SLC29A2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL27846989	1.00	2/20
SCHEMBL18542996	0.79	2/20
SCHEMBL18542998	0.65	2/20
SCHEMBL18543003	0.65	2/20
SCHEMBL21530475	0.62	2/20
SCHEMBL24019197	0.61	2/20
SCHEMBL6307060	0.59	2/20
SCHEMBL15662479	0.58	2/20
SCHEMBL21530456	0.54	2/20
SCHEMBL15660651	0.77	1/20
SCHEMBL17999847	0.69	1/20
SCHEMBL17999762	0.67	1/20
SCHEMBL30100838	0.67	1/20
SCHEMBL15662302	0.65	1/20
SCHEMBL15658933	0.65	1/20
SCHEMBL26317590	0.64	1/20
SCHEMBL17999785	0.62	1/20
SCHEMBL24019198	0.57	1/20
SCHEMBL15660042	0.57	1/20
SCHEMBL18029452	0.57	1/20

Clinical trials — most relevant to SLC29A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE3	COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir	PHASE2	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine	PHASE1	COMPLETED
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer	nan	UNKNOWN
Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Characterization of Breg Cells	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis	nan	RECRUITING
Placental Transfer of Tenofovir	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC29A2 binder may also engage these)

Protein	Name	Similarity
O54699	—	1.000	O54699 →
Q61672	—	1.000	Q61672 →
Q99P65	—	0.995	Q99P65 →
Q80WK7	—	0.995	Q80WK7 →
A1A4N1	—	0.993	A1A4N1 →
Q9BZD2	—	0.992	Q9BZD2 →
O54698	—	0.989	O54698 →
Q9JIM1	—	0.989	Q9JIM1 →
Q5E9R1	—	0.986	Q5E9R1 →
A2VE54	—	0.984	A2VE54 →
Q9NQ40	—	0.984	Q9NQ40 →
Q6GMG6	—	0.983	Q6GMG6 →
SLC29A1	Equilibrative nucleoside transporter 1	0.982	landscape →
Q4FZU9	—	0.982	Q4FZU9 →
B0S5Y3	—	0.982	B0S5Y3 →
C1BKZ7	—	0.981	C1BKZ7 →
B5X4H8	—	0.980	B5X4H8 →
D2HSA6	—	0.980	D2HSA6 →
Q710D3	—	0.979	Q710D3 →
Q9D6X5	—	0.977	Q9D6X5 →
P48056	—	0.977	P48056 →
Q86WB7	—	0.976	Q86WB7 →
Q8K0H7	—	0.976	Q8K0H7 →
P31651	—	0.976	P31651 →
O43246	—	0.976	O43246 →
Q96N87	—	0.975	Q96N87 →
B2RXV4	—	0.975	B2RXV4 →
P23562	—	0.974	P23562 →
P48055	—	0.974	P48055 →
P27799	—	0.974	P27799 →